Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-04991532 alone · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| PF-04991532 alone | EXPERIMENTAL | - |
| PF-04991532 + cyclosporine | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| PF-04991532 alone | DRUG | a single dose of 150 mg PF-04991532, fasted |
| PF-04991532 + cyclosporine | DRUG | a single dose of 150 mg PF-04991532 + a single dose of 600 mg cyclosporine, fasted |
Inclusion Criteria: * Healthy male and/or female (non-childbearing potential) subjects between the ages of 18 and 55 years, inclusive. Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse r...
PF-04991532 is an investigational small molecule developed by Pfizer, Inc. (ticker PFE). It is a glucokinase (GCK) activator that has been studied in Phase 1 clinical research. The specific disease or condition it is intended to treat has not been publicly disclosed, and it remains in early-stage clinical development.
PF-04991532 targets glucokinase, also known as GCK. It acts as a GCK activator, meaning it is designed to increase the activity of this enzyme. Glucokinase plays a role in glucose metabolism, which is why GCK activators are studied as a drug class.
PF-04991532 is developed by Pfizer, Inc., which trades under the ticker symbol PFE. Pfizer sponsored the clinical research conducted on this compound, including a Phase 1 drug interaction study run in Belgium.
PF-04991532 is in Phase 1 clinical development. It is an investigational drug and is not approved by the FDA. Only one clinical trial has been recorded for this compound, and that trial is now completed, with no active trials currently listed.
PF-04991532 has been studied in one completed Phase 1 trial, NCT01370343, titled a single dose study of the effect of cyclosporine on the pharmacokinetics of PF-04991532 in healthy volunteers. That trial enrolled 12 participants in Belgium and examined a drug interaction in healthy adults.
Yes. The Phase 1 trial of PF-04991532, NCT01370343, was randomized and controlled, though it was not double-blind. It enrolled 12 healthy volunteers aged 18 years and older in Belgium and has been completed. No biomarker-based patient selection was used in this study.